Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
Murphy ST, Alton G, Bailey S, Baxi SM, Burke BJ, Chappie TA, Ermolieff J, Ferre R, Greasley S, Hickey M, Humphrey J, Kablaoui N, Kath J, Kazmirski S, Kraus M, Kupchinsky S, Li J, Lingardo L, Marx MA, Richter D, Tanis SP, Tran K, Vernier W, Xie Z, Yin MJ, Yu XH. Murphy ST, et al. J Med Chem. 2011 Dec 22;54(24):8490-500. doi: 10.1021/jm201019k. Epub 2011 Nov 23. J Med Chem. 2011. PMID: 22040023
Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.
Baxi SM, Tan W, Murphy ST, Smeal T, Yin MJ. Baxi SM, et al. Among authors: murphy st. PLoS One. 2012;7(10):e48402. doi: 10.1371/journal.pone.0048402. Epub 2012 Oct 31. PLoS One. 2012. Retraction in: PLoS One. 2017 Apr 10;12(4):e0175772. doi: 10.1371/journal.pone.0175772 PMID: 23119004 Free PMC article. Retracted.
Time-dependent inhibition of PHD2.
Tcholakov I, Grimshaw CE, Shi L, Kiryanov A, Murphy ST, Larson CJ, Plonowski A, Ermolieff J. Tcholakov I, et al. Among authors: murphy st. Biosci Rep. 2017 Jun 30;37(3):BSR20170275. doi: 10.1042/BSR20170275. Print 2017 Jun 30. Biosci Rep. 2017. PMID: 28592559 Free PMC article.
The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.
Murphy ST, Case HL, Ellsworth E, Hagen S, Huband M, Joannides T, Limberakis C, Marotti KR, Ottolini AM, Rauckhorst M, Starr J, Stier M, Taylor C, Zhu T, Blaser A, Denny WA, Lu GL, Smaill JB, Rivault F. Murphy ST, et al. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2150-5. doi: 10.1016/j.bmcl.2007.01.090. Epub 2007 Feb 2. Bioorg Med Chem Lett. 2007. PMID: 17303420
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.
Murphy ST, Atienza J, Brown JW, Cheruvallath ZS, Cukierski MJ, Fabrey R, Keung W, Kwok L, O'Connell S, Tang M, Vanderpool DL, Vincent PW, Zhang L, Marx MA. Murphy ST, et al. ACS Med Chem Lett. 2023 Oct 25;14(11):1544-1550. doi: 10.1021/acsmedchemlett.3c00351. eCollection 2023 Nov 9. ACS Med Chem Lett. 2023. PMID: 37970587 Free PMC article.
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
Warmus JS, Quinn CL, Taylor C, Murphy ST, Johnson TA, Limberakis C, Ortwine D, Bronstein J, Pagano P, Knafels JD, Lightle S, Mochalkin I, Brideau R, Podoll T. Warmus JS, et al. Among authors: murphy st. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2536-43. doi: 10.1016/j.bmcl.2012.01.140. Epub 2012 Feb 16. Bioorg Med Chem Lett. 2012. PMID: 22401863
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.
Sun H, Monenschein H, Schiffer HH, Reichard HA, Kikuchi S, Hopkins M, Macklin TK, Hitchcock S, Adams M, Green J, Brown J, Murphy ST, Kaushal N, Collia DR, Moore S, Ray WJ, English NM, Carlton MBL, Brice NL. Sun H, et al. Among authors: murphy st. J Med Chem. 2021 Jul 22;64(14):9875-9890. doi: 10.1021/acs.jmedchem.0c02081. Epub 2021 Apr 16. J Med Chem. 2021. PMID: 33861086
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease.
Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, Xu X, Cheung T, Burley JR, Sun H, Dickson L, Murphy ST, Kaushal N, Sheardown S, Lawrence J, Chen Y, Bartkowski D, Kanta A, Russo J, Hosea N, Dawson LA, Hitchcock SH, Carlton MB. Brice NL, et al. Among authors: murphy st. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416. doi: 10.1124/jpet.120.000438. Epub 2021 Apr 1. J Pharmacol Exp Ther. 2021. PMID: 33795395
142 results